Member Exclusive News

The week in industry: AstraZeneca announces three, global-medicine R&D initiatives in China

This week: Sandoz (Holzkirchen, Germany) receives US FDA approval for its febrile neutropenia-induced infection treatment, Biogen (MA, USA) seeks to expand its biosimilar portfolio and an international collaboration aims to develop DNA damage response inhibitors.

Go to the profile of RxNet
Nov 07, 2019
0
0

Please sign in or register for FREE

No comments yet.